3 min read

Controlled substances in Switzerland: documentation and accountability

This article explains how the Swiss framework works and why its documentation requirements are a model of accountability.
Controlled substances in Switzerland

Opioids, stimulants for ADHD and certain sedatives are essential medicines. They are also open to misuse, diversion and dependence. That is why they are regulated by a separate legal framework on top of general medicines law, with stricter rules for prescribing, storage and record-keeping.

As a pharmacist in Switzerland, I handle controlled substances regularly. This article explains how the Swiss framework works and why its documentation requirements are a model of accountability.

Controlled substances in Switzerland are regulated mainly by:

  • the Narcotics Act (BetmG), which sets the principles;
  • the Narcotics Control Ordinance (BetmKV), which details prescribing, dispensing, storage and record-keeping;
  • the directory ordinance of the Federal Department of Home Affairs (BetmVV-EDI), which lists controlled substances in categories.

Swissmedic oversees controlled substances in the pharmaceutical trade, including licences for companies (Narcotics Act [BetmG], 1951), while the cantons supervise pharmacies, doctors and hospitals (BetmG, 1951).

The lists: different levels of control

The directory sorts substances into lists that determine how strictly they are controlled. In simplified terms (Ordinance of the FDHA on the Lists of Narcotics [BetmVV-EDI], 2011):

  • List a contains substances subject to all control measures, such as strong opioids and methylphenidate.
  • List b contains substances partly exempted from some controls.
  • List c contains preparations with low amounts of controlled substances, largely exempted.
  • List d contains prohibited substances.

The list determines the type of prescription required and the documentation the pharmacy must keep. Checking the list status of a product is therefore the first step for any controlled substance.

Prescriptions: special forms and limits

For list a substances, prescriptions must be written on an official narcotics prescription form (Narcotics Control Ordinance [BetmKV], 2011). The prescription must contain the patient details, the substance, the dose, the dosage instructions and the prescriber's signature.

The quantity is generally limited to a supply for one month. The prescriber can extend this to up to three months when there is a justified reason stated on the prescription (BetmKV, 2011).

At dispensing, the pharmacist checks the form carefully: completeness, validity, plausibility of the dose and consistency with the patient's history. Any doubt is clarified with the prescriber before dispensing.

Storage: secure and separate

Controlled substances must be stored securely, protected from unauthorised access. In practice, list a products are kept locked and separate from other stock, with access limited to authorised staff (BetmKV, 2011).

Secure storage is not only about theft by outsiders. Clear access rules also protect staff and make any discrepancy easier to investigate.

Documentation: every unit accounted for

The core of the system is accountability. For list a substances, the pharmacy keeps records of every movement:

  • receipts from suppliers;
  • dispensing to patients, linked to the prescription;
  • returns and destruction;
  • current stock balance.

Regular reconciliation compares the recorded balance with the physical stock. Any discrepancy must be investigated and documented. Records are kept for the legally required period and must be available to the cantonal authorities on request (BetmKV, 2011).

The destruction of expired or returned controlled substances is also documented, so that nothing disappears from the record without explanation.

The patient safety side

Controlled substance regulation is not only about preventing diversion. It is also about protecting patients from harm.

In daily practice, that means:

  • noticing early refill requests or prescriptions from multiple doctors;
  • checking for dangerous combinations, such as opioids with benzodiazepines, which increase the risk of respiratory depression (Park et al., 2015);
  • counselling patients on safe use, storage at home and disposal;
  • recognising signs of dependence and discussing concerns with the prescriber.

The industry perspective

Pharmaceutical companies that manufacture, import, export or distribute controlled substances need specific licences and permits. Their warehouses apply the same principles at larger scale: restricted access, reconciliation, documented destruction and full traceability.

Quality assurance and logistics teams play a key role here. A small discrepancy in a controlled substance inventory can trigger a formal investigation and reporting to the authorities.

Why this matters to employers

Controlled substances show regulated documentation at its most demanding. Every unit must be traceable, every discrepancy explained, and every record available for inspection.

My experience handling controlled substances in Swiss pharmacies, together with years of prescription and inventory control in hospital and community settings, has made this level of accountability routine for me. It transfers directly to quality, logistics and compliance roles in industry.

Key takeaways

  • Swiss controlled substances follow the BetmG, BetmKV and the BetmVV-EDI lists.
  • List a substances need official prescription forms, secure storage and complete movement records.
  • Accountability protects both public health and individual patients.

References

Narcotics Act [BetmG] of 3 October 1951, SR 812.121 (Switzerland). https://www.fedlex.admin.ch

Narcotics Control Ordinance [BetmKV] of 25 May 2011, SR 812.121.1 (Switzerland). https://www.fedlex.admin.ch

Ordinance of the FDHA on the Lists of Narcotics, Psychotropic Substances, Precursors and Auxiliary Chemicals [BetmVV-EDI] of 30 May 2011, SR 812.121.11 (Switzerland). https://www.fedlex.admin.ch

Park, T. W., Saitz, R., Ganoczy, D., Ilgen, M. A., & Bohnert, A. S. B. (2015). Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: Case-cohort study. BMJ, 350, h2698. https://doi.org/10.1136/bmj.h2698